Instinct Bio and INVITRX Join Forces to Bring GENREVER to U.S. and Boost Indonesia's Regenerative Medicine Efforts

Instinct Bio Technical Company Holdings Inc. (Nasdaq: BIOT) announced today that its subsidiaries have entered into a Memorandum of Agreement with Invitrx Therapeutics, Inc. (INVITRX) to establish a strategic framework for two proposed workstreams: the manufacture and sale of GENREVER cosmetic products in the United States and the potential supply of concentrated exosomes and conditioned media for clinics and an in-hospital cell processing center in Indonesia.

This collaboration builds upon a proven six-year commercial relationship under which Instinct Bio has sourced certain principal raw materials from INVITRX for use in its products. The company believes this existing relationship may facilitate coordination as the parties evaluate the proposed collaboration.

Under the proposed collaboration, Instinct Bio intends to license the GENREVER trademark, and its subsidiary Artisans Production will contribute proprietary formulations and raw materials. INVITRX is expected to manufacture GENREVER products at its U.S. GMP manufacturing facility, positioning GENREVER as a premium Japanese cosmetics brand for the U.S. market, subject to applicable regulatory requirements.

In Indonesia, the parties intend to collaborate on initiatives supporting proposed clinics and an in-hospital cell processing center and laboratory. Subject to regulatory requirements, INVITRX is expected to supply concentrated exosomes and conditioned media while the parties evaluate opportunities to establish a localized regenerative medicine platform in one of Asia's rapidly growing healthcare markets.

The parties intend to negotiate definitive commercial agreements covering manufacturing, supply, commercialization and other operating arrangements while progressing regulatory assessments required for each initiative.

Tomoki Nagano, Chief Executive Officer of Instinct Bio, stated: "This collaboration represents an important step in our strategy to expand Instinct Bio's international platform. By bringing together the GENREVER brand, Artisans Production's proprietary formulations and INVITRX's U.S. GMP manufacturing capabilities, we believe we are creating a strong foundation for future growth in both the United States and Southeast Asia."

Instinct Bio is a biotechnology company focused on regenerative medicine, longevity-related technologies and advanced therapeutic platforms. For more information, visit https://instinct-biot.com/.

INVITRX is a U.S.-based biotechnology company that operates a GMP manufacturing facility and develops and supplies cell-derived biological materials, including concentrated exosomes and conditioned media.

This press release contains forward-looking statements, and the MOA establishes a framework for negotiation; there can be no assurance that definitive agreements will be entered into or that the proposed collaboration will be completed.